BRAF and melanoma: Besides, in melanoma patients, both the BRAF wild type and BRAF mutant patients benefited in OS, and HRs (95%CIs) were 0.51, (0.45, 0.58), p < 0.001; 0.55, (0.44, 0.69), p < 0.001 respectively with not important heterogeneity (I2 = 2.7%; I2 = 8.0%) (Figure 5).